Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

277 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A monocentric, open-label randomized standard-of-care controlled study of XONRID®, a medical device for the prevention and treatment of radiation-induced dermatitis in breast and head and neck cancer patients.
Ingargiola R, De Santis MC, Iacovelli NA, Facchinetti N, Cavallo A, Ivaldi E, Dispinzieri M, Franceschini M, Giandini C, Romanello DA, Di Biaso S, Sabetti M, Locati L, Alfieri S, Bossi P, Guglielmo M, Macchi F, Lozza L, Valdagni R, Fallai C, Pignoli E, Orlandi E. Ingargiola R, et al. Among authors: guglielmo m. Radiat Oncol. 2020 Aug 13;15(1):193. doi: 10.1186/s13014-020-01633-0. Radiat Oncol. 2020. PMID: 32791985 Free PMC article. Clinical Trial.
Prevalence of Fatigue in Head and Neck Cancer Survivors.
Bossi P, Di Pede P, Guglielmo M, Granata R, Alfieri S, Iacovelli NA, Orlandi E, Guzzo M, Bianchi R, Ferella L, Infante G, Miceli R, Licitra L, Ripamonti CI. Bossi P, et al. Among authors: guglielmo m. Ann Otol Rhinol Laryngol. 2019 May;128(5):413-419. doi: 10.1177/0003489419826138. Epub 2019 Jan 30. Ann Otol Rhinol Laryngol. 2019. PMID: 30700107
A randomized, double-blind, placebo controlled, phase II study to evaluate the efficacy of ginseng in reducing fatigue in patients treated for head and neck cancer.
Guglielmo M, Di Pede P, Alfieri S, Bergamini C, Platini F, Ripamonti CI, Orlandi E, Iacovelli NA, Licitra L, Maddalo M, Bossi P. Guglielmo M, et al. J Cancer Res Clin Oncol. 2020 Oct;146(10):2479-2487. doi: 10.1007/s00432-020-03300-z. Epub 2020 Jul 2. J Cancer Res Clin Oncol. 2020. PMID: 32617701 Clinical Trial.
Pre-treatment risk factors to predict early cisplatin-related nephrotoxicity in locally advanced head and neck cancer patients treated with chemoradiation: A single Institution experience.
Cavalieri S, Platini F, Barretta F, Nuzzolese I, Ottini A, Bergamini C, Resteghini C, Colombo E, Iacovelli NA, Franceschini M, Calareso G, Di Pede P, De Feo G, Gandelli M, Toffolatti L, Guglielmo M, Ripamonti CI, Cosmai L, Licitra L, Alfieri S. Cavalieri S, et al. Among authors: guglielmo m. Oral Oncol. 2023 Nov;146:106579. doi: 10.1016/j.oraloncology.2023.106579. Epub 2023 Sep 29. Oral Oncol. 2023. PMID: 37778228
Italian version of the Edmonton Symptom Assessment System (ESAS)-Total Care (TC): development and psychometric validation in patients undergoing cancer treatment or follow-up.
Ripamonti C, Leporati R, De Feo G, Di Pede P, Toffolatti L, Guglielmo M, La Carpia D, Miccinesi G, Chiesi F. Ripamonti C, et al. Among authors: guglielmo m. Support Care Cancer. 2022 Mar;30(3):1923-1933. doi: 10.1007/s00520-021-06594-y. Epub 2021 Oct 8. Support Care Cancer. 2022. PMID: 34623487
277 results